EGFR and neoplasm: In mice bearing patient-derived LU0858 tumors (harboring the EGFR-activating L858R mutation and METamp), gefitinib and afatinib had no inhibitory effect on tumor growth whereas tepotinib alone delayed tumor growth significantly, and tepotinib combined with EGFR-TKIs caused complete tumor regression (60).